<p>Pivot</p> <p> (invalidation): 1.1555 Our preference</p> <p>Long positions above 1.1555 with targets at 1.1585 & 1.1600 in extension.</p> <p&g
<p>Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics
Leave a Comment